If you purchased, paid, or provided reimbursement for some or all of the purchase price of branded Lipitor® or generic atorvastatin calcium, you could get a payment from a class-action lawsuit.
A proposed Settlement has been reached in a class-action lawsuit against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, “Pfizer”) and Ranbaxy Inc., Ranbaxy Laboratories Limited, and Ranbaxy Pharmaceuticals, Inc. (collectively, “Ranbaxy”). The lawsuit claims that Pfizer and Ranbaxy unlawfully kept generic versions of Lipitor off the market, so consumers and third-party payors paid more for brand and generic Lipitor than they should have. Pfizer and Ranbaxy deny that they did anything wrong.
There has been a Settlement with Pfizer. The case against Ranbaxy remains ongoing.
A $35 million Settlement Fund will pay (1) money to eligible Third-Party Payor and Consumer Class Members; (2) notice and administration costs; (3) service awards to the class representatives who brought the lawsuit; and (4) attorneys’ fees, costs, and expenses.
These rights and options—and the deadlines to exercise them—are explained in the Notice and on the Frequently Asked Questions (FAQ) page of this website. The Court in charge of this case still must decide whether to approve the Settlement. Payments will be made to those who qualify only after the Court approves the Settlement and any appeals are resolved. Please be patient.